Inflammatory signaling blocks NUMB’s ability to deaden NOTCH1-driven tumor development
MD Anderson News Release
HOUSTON — An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.
Working in...
Branson, O’Brien available for media questions at 1:30-2 p.m. press conference immediately following program. Contact MD Anderson...
MD Anderson News Release 12/14/11
The holidays are here, and The University of Texas MD Anderson Cancer Center Children's Art Project...
Identification of varied survival prospects may guide care for patients whose myelodysplastic syndrome stems from radiation, chemotherapy
MD Anderson News Release 12/13/11
A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis, researchers from The University of Texas MD Anderson Cancer Center report...
National Phase III clinical trial will test histone deacetylase inhibitor with frontline therapy
MD Anderson News Release...
PCI-32765 applies molecularly aimed attack to disease usually treated with chemotherapy combinations
MD Anderson News...
MD Anderson News Release 12/07/11
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy...
UT MD Anderson experts share advice on how to avoid holiday weight gain
MD Anderson News Release 12/6/11
Holiday...
Dallas 'Conversation' With Miles O'Brien to Raise Funds for Cancer Research, Patient Care
MD Anderson News Release 12/...
MD Anderson News Release 12/06/11
Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy...